Compare Biogen Inc (BIIB) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Fubotv Inc — how do they compare? Biogen Inc trades at $196.49 (market cap $28.34B), while Fubotv Inc trades at $10.09 (market cap $280.89M). The key difference: Biogen Inc is far larger — about 100.9× Fubotv Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | FUBO | |
|---|---|---|
Market Cap | $28.34B | $280.89M |
Sector | Health | Technology |
52-Week High | $216.63 | $54.72 |
52-Week Low | $122.68 | $8.09 |
Enterprise Value | $30.62B | $451.31M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
FUBO trades at $9.83, up 7.08% today, with technical indicators showing neutral signals. The company reported a net loss of $172.25M in 2024, but revenue grew to $1.62B and net income is projected to turn positive in 2025. Recent CEO appointment from Disney has driven positive sentiment, while valuation ratios like P/E of 2.56 and P/S of 0.2 appear attractive relative to historical norms.
Outlook is cautiously optimistic with analyst consensus price target of $16.25 implying 65% upside, supported by streaming growth and new partnerships. Key risks include persistent cash burn and intense competition in the streaming sector. The stock offers value if profitability targets are met, but requires monitoring of subscriber trends and execution on cost controls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
